Insulet initiated with an Outperform at RBC Capital

RBC Capital analyst Shagun Singh initiated coverage of Insulet (PODD) with an Outperform rating and $340 price target The firm says Insulet has a “differentiated” technology offering with the only available patch automated insulin delivery system on the market and competitive advantages. Key opinion leader checks suggest upside to consensus/ estimates, driven by global Omnipod 5, the analyst tells investors in a research note. Further, RBC sees at least 100 basis points of annual margin expansion, driving 26% annual earnings growth over Insulet’s next three years and the stock higher.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue